UK-based AI-driven drug discovery and precision medicine company Zephyr AI has emerged from stealth to develop novel therapeutics, new applications for existing therapeutics, and generate biomarkers for precision medicine.
The company will leverage its AI technology to analyze large sets of medical data. It published its first discovery—the potential of antibiotic azithromycin for lung cancer treatment—in the journal Oncogene in May 2021, which utilized publicly available datasets. It is currently working with pharma companies, payers, and providers to expand its database.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.